Programs
COVAX Vaccine Distribution
WITH ITS FIRST DELIVERIES COMMENCING IN JANUARY 2021, COVAX DELIVERED NEARLY 1.9 BILLION DOSES OF VACCINES TO PEOPLE IN 146 ECONOMIES BY THE END OF 2022. APPROXIMATELY 90% OF THESE DOSES HAVE GONE TO LOWER-INCOME ECONOMIES REPRESENTING THE FASTEST AND MOST COMPLEX GLOBAL DEPLOYMENT OF VACCINES EVER.FURTHER INFORMATION ON GAVI'S COVAX REPORT CAN BE FOUND IN ITS 2022 ANNUAL PROGRESS REPORT, ONLINE AT: HTTPS://WWW.GAVI.ORG/PROGRAMMES-IMPACT/OUR-IMPACT/PROGRESS-REPORTS.GeographiesNot indicatedDatesJan 1, 2022 – Dec 31, 2022Source990No causes providedNo populations provided–$5.6BThe Vaccine Goal
THE VACCINE GOAL: INTRODUCE AND SCALE UP VACCINESINCLUDING ROUTINE, PREVENTIVE CAMPAIGN AND COVID-19 VACCINATIONS, THE 57 GAVI-SUPPORTED COUNTRIES ADMINISTERED NEARLY THREE TIMES AS MANY VACCINE DOSES IN 2022 AS IN 2020.- 40 GAVI-SUPPORTED VACCINE INTRODUCTIONS AND PREVENTIVE CAMPAIGNS TOOK PLACE IN 2022 - IN ADDITION TO 40 OUTBREAK RESPONSE VACCINATION CAMPAIGNS SUPPORTED BY GAVI.- 4 KEY SUSTAINABLE DEVELOPMENT GOAL (SDG) VACCINES SAW AN INCREASE IN COVERAGE AMONG THE 57 GAVI-SUPPORTED COUNTRIES SINCE 2021.- 20 COUNTRIES ACCESSED EMERGENCY STOCKPILES FOR CHOLERA, EBOLA, MENINGOCOCCAL AND YELLOW FEVER VACCINES A TOTAL OF 33 TIMES IN 2022.- BREADTH OF PROTECTION WITH VACCINES IN THE GAVI PORTFOLIO IS NOW HIGHER IN GAVI-SUPPORTED COUNTRIES (56%) THAN IN THE REST OF THE WORLD (53%), AND IS UP 5 PERCENTAGE POINTS FROM 2021.THE EQUITY GOAL: STRENGTHEN HEALTH SYSTEMS TO INCREASE EQUITY IN IMMUNIZATIONIN GAVI 5.0/5.1, HEALTH SYSTEM STRENGTHENING (HSS) SUPPORT PRIORITISES EQUITY IN IMMUNISATION DELIVERY, TO REDUCE THE NUMBER OF ZERO-DOSE AND UNDER-IMMUNISED CHILDREN.- 2.6 MILLION MORE CHILDREN RECEIVED BASIC ROUTINE IMMUNISATIONS THROUGH GAVI-SUPPORTED HEALTH SYSTEMS IN 2022 THAN IN 2021.- 47 COUNTRIES HAVE INSTALLED MORE THAN 65,000 COLD CHAIN EQUIPMENT (CCE) UNITS PROCURED BY UNICEF SUPPLY DIVISION THROUGH GAVI'S COLD CHAIN EQUIPMENT OPTIMISATION PLATFORM (CCEOP) - NEARLY 13, 000 IN 2022 ALONE.- 17.2 MILLION IMMUNISATION SESSIONS WERE REPORTED IN GAVI-SUPPORTED COUNTRIES IN 2022.- 25 GAVI-SUPPORTED COUNTRIES INCREASED FIRST DOSE OF MEASLES-CONTAINING VACCINE (MCV1) COVERAGE FROM 2021 TO 2022, BUT MEASLES IMMUNITY GAPS REMAIN A SIGNIFICANT CONCERN.- IN 2022, DIPHTHERIA, PERTUSSIS AND TETANUS-CONTAINING VACCINE (DTP3) COVERAGE IN GAVI-SUPPORTED COUNTRIES REBOUNDED TO 81% AFTER TWO YEARS OF DECLINE (COMPARED TO THE 84% GLOBAL AVERAGE).THE SUSTAINABILITY GOAL: IMPROVE SUSTAINABILITY OF NATIONAL IMMUNIZATION PROGRAMMESTHE YEAR 2022 CONFIRMED THE ROBUSTNESS OF THE VACCINE ALLIANCE'S CO-FINANCING APPROACH AND THE STEADY FINANCIAL COMMITMENT OF COUNTRIES DESPITE RISING DEBT LEVELS AND THE WAR IN UKRAINE.- US $162 MILLION WAS CONTRIBUTED BY COUNTRIES TOWARDS THE CO-FINANCING OF GAVI-SUPPORTED VACCINES IN 2022 - THE HIGHEST AMOUNT YET AND A TESTAMENT TO COUNTRY OWNERSHIP AND THE LONG-TERM FINANCIAL SUSTAINABILITY OF GAVI-SUPPORTED VACCINES.- 54 VACCINE PROGRAMMES ORIGINALLY INTRODUCED WITH GAVI FUNDING ARE NOW SELF-FINANCED BY COUNTRIES AS OF 2022, UP FROM 40 IN 2018.- 100% OF COUNTRIES FULLY MET THEIR 2022 CO-FINANCING OBLIGATION - EXCEPT THREE WAIVERS FOR HUMANITARIAN CRISIS.- IN THE FACE OF FISCAL CHALLENGES, CLIMATE CHANGE, CONFLICT AND INSTABILITY, MOST GAVI-SUPPORTED COUNTRIES MAINTAINED OR INCREASED DOMESTIC RESOURCES FOR CO-FINANCING OF GAVI-SUPPORTED VACCINES IN 2022, BRINGING TO US$ 1.5 BILLION THEIR TOTAL CONTRIBUTION SINCE THE INTRODUCTION OF THE CO-FINANCING POLICY IN 2018.THE HEALTHY MARKETS GOAL: ENSURE HEALTHY MARKETS FOR VACCINES AND RELATED PRODUCTSGAVI'S MARKET SHAPING EFFORTS MAKE LIFE-SAVING VACCINES AND OTHER IMMUNISATION PRODUCTS MORE ACCESSIBLE AND AFFORDABLE FOR LOWER-INCOME COUNTRIES.- 10 MARKETS FOR VACCINES AND IMMUNISATION PRODUCTS EXHIBITED ACCEPTABLE LEVELS OF HEALTHY MARKET DYNAMICS IN 2022, MEETING THE TARGET FOR THE YEAR.- 9 INNOVATIVE PRODUCTS WERE WITHIN THE PIPELINE OF COMMERCIAL-SCALE MANUFACTURERS IN 2022, MEETING THE ALLIANCE TARGET OF 8 BY 2025 WELL AHEAD OF SCHEDULE.- 2 NEW PRODUCTS WITH IMPROVED CHARACTERISTICS WERE NEWLY OFFERED TO GAVI-SUPPORTED COUNTRIES IN 2022: A NEW LIQUID ROTAVIRUS VACCINE, IMPROVING EASE OF DELIVERY FOR HEALTH CARE WORKERS; AND A NEW PRESENTATION FOR YELLOW FEVER VACCINE, IMPROVING ITS COLD CHAIN FOOTPRINT.- THROUGH GAVI'S MARKET SHAPING EFFORTS, THE NUMBER OF MANUFACTURERS SUPPLYING PREQUALIFIED GAVI-SUPPORTED VACCINES HAS GROWN FROM 5 IN 2001 TO 19 IN 2022 (WITH MORE THAN HALF BASED IN LOW- AND MIDDLE-INCOME COUNTRIES).FURTHER INFORMATION ON GAVI'S PROGRESS TOWARDS ACHIEVING ITS STRATEGIC GOALS CAN BE FOUND IN ITS 2022 ANNUAL PROGRESS REPORT, ONLINE AT: HTTPS://WWW.GAVI.ORG/PROGRAMMES-IMPACT/OUR-IMPACT/PROGRESS-REPORTS.GeographiesNot indicatedDatesJan 1, 2022 – Dec 31, 2022Source990No causes providedNo populations provided–$1.7B
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)